Phase 2 Sickle Cell Disease Trial, Recruiting NCT03121001 Sponsor: University of Illinois at Chicago Condition: Sickle Cell Disease
Back to Sickle Cell Disease

Phase 2 Sickle Cell Disease Trial, Recruiting

NCT03121001
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People diagnosed with sickle cell disease who have experienced at least one of the following complications: a stroke or nervous system event lasting more than 24 hours; frequent severe pain episodes (3 or more per year needing emergency care, hospital admission, or home bedrest causing missed work or school); repeated episodes of painful, prolonged erections (2 or more per year needing emergency care); recurring hospitalizations for a serious lung condition called acute chest syndrome (2 or more times in their lifetime); development of 2 or more blood antibodies during long-term blood transfusion treatment; serious vision problems in at least one eye due to abnormal blood vessel growth; bone damage in 2 or more joints; reduced kidney function or high levels of protein in the urine; or high blood pressure in the lungs
  • People aged between 16 and 60 years old
  • People who are well enough to carry out most daily activities (as measured by a standard health scoring tool — confirm with trial site)
  • People whose heart is pumping adequately (as assessed by a specific heart function test — confirm with trial site)
  • People whose lungs are working adequately (as assessed by a specific breathing test — confirm with trial site)
  • People whose kidneys are functioning at a sufficient level (as measured by a standard kidney function calculation — confirm with trial site)
  • People whose liver enzyme levels are not significantly elevated (confirm with trial site)
  • People who test negative for HIV
  • People who are not pregnant
  • People who are willing and able to sign a consent form agreeing to take part
  • People who do not have a fully matched brother or sister available to donate stem cells
  • People who have a half-matched (haploidentical) blood relative willing to donate — this includes parents, children, siblings, aunts, uncles, or cousins

Who may not be able to join:

  • People who do not have a half-matched relative available to donate stem cells
  • People who have a fully matched sibling donor available and willing to donate stem cells, as the trial site would not consider them eligible for this particular study
  • People who are pregnant
  • People who test positive for HIV
  • People whose heart, lung, or kidney function does not meet the minimum levels required by the trial (confirm exact thresholds with trial site)
  • People whose liver enzyme levels are too high (confirm with trial site)
  • People who are unable or unwilling to sign the informed consent form

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Damiano Rondelli, MD, University of Illinois at Chicago

Phone: 312 413-3547

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
University of Illinois at Chicago
Registry
ClinicalTrials.gov
Start date
20 March 2017
Est. completion
1 May 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Estimate the number of patients who engraft by Day +60

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov